Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX, designed to treat a broad range of diseases including cancer, autoimmune, and infectious diseases [4] - The company leverages its proprietary ImmTAX platform to develop a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease, and multiple earlier pre-clinical programs [4] - Immunocore's most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom [4] Upcoming Event - Immunocore management will participate in a presentation at the 43rd Annual J P Morgan Healthcare Conference in San Francisco, California, scheduled for Wednesday, January 15, 2025, at 8:15 a m Pacific Standard Time (PST) [2][3] - The presentation will be webcast live and accessible via the "Events & Presentations" section under "Investors" on Immunocore's website, with a replay available for a limited time following the event [3]